Sara Bonstein Sells 13,302 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 13,302 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $80.00, for a total transaction of $1,064,160.00. Following the sale, the chief financial officer now owns 142,204 shares in the company, valued at approximately $11,376,320. This trade represents a 8.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Sara Bonstein also recently made the following trade(s):

• On Thursday, February 6th, Sara Bonstein sold 28,390 shares of Insmed stock. The shares were sold at an average price of $80.90, for a total transaction of $2,296,751.00.
• On Friday, January 10th, Sara Bonstein sold 1,066 shares of Insmed stock. The shares were sold at an average price of $63.72, for a total transaction of $67,925.52.
• On Tuesday, January 7th, Sara Bonstein sold 3,470 shares of Insmed stock. The shares were sold at an average price of $65.70, for a total transaction of $227,979.00.

Insmed Stock Up 0.8 %

Shares of NASDAQ:INSM opened at $79.31 on Friday. The stock has a market cap of $14.19 billion, a P/E ratio of -14.29 and a beta of 1.11. The firm has a fifty day moving average price of $73.38 and a 200 day moving average price of $73.28. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $82.04.

Institutional Trading of Insmed

A number of large investors have recently bought and sold shares of the business. Truist Financial Corp acquired a new stake in shares of Insmed in the 2nd quarter worth $413,000. GAMMA Investing LLC lifted its stake in shares of Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 224 shares during the period. Exchange Traded Concepts LLC lifted its stake in shares of Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 627 shares during the period. Creative Planning lifted its stake in shares of Insmed by 31.2% in the 3rd quarter. Creative Planning now owns 44,914 shares of the biopharmaceutical company’s stock worth $3,279,000 after acquiring an additional 10,668 shares during the period. Finally, V Square Quantitative Management LLC acquired a new stake in shares of Insmed in the 3rd quarter worth $30,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on INSM shares. Truist Financial reissued a “buy” rating and issued a $105.00 price objective (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. Stifel Nicolaus increased their price objective on shares of Insmed from $88.00 to $97.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th. Morgan Stanley increased their target price on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Guggenheim increased their target price on shares of Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $88.71.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.